#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Extracellular vesicles ( EVs ) are cell-derived membrane vesicles that represent an endogenous mechanism for intercellular communication .
2-1	16-29	Extracellular	object[2]	new[2]	_	_
2-2	30-38	vesicles	object[2]	new[2]	_	_
2-3	39-40	(	_	_	_	_
2-4	41-44	EVs	abstract	new	coref	3-1
2-5	45-46	)	_	_	_	_
2-6	47-50	are	_	_	_	_
2-7	51-63	cell-derived	_	_	_	_
2-8	64-72	membrane	object|object[5]	new|new[5]	coref|coref|coref|coref	3-8[11_5]|3-53|3-8[11_5]|3-53
2-9	73-81	vesicles	object[5]	new[5]	_	_
2-10	82-86	that	_	_	_	_
2-11	87-96	represent	_	_	_	_
2-12	97-99	an	abstract[6]	new[6]	_	_
2-13	100-110	endogenous	abstract[6]	new[6]	_	_
2-14	111-120	mechanism	abstract[6]	new[6]	_	_
2-15	121-124	for	abstract[6]	new[6]	_	_
2-16	125-138	intercellular	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-17	139-152	communication	abstract[6]|abstract[7]	new[6]|new[7]	_	_
2-18	153-154	.	_	_	_	_

#Text=EVs can be classified in exosomes , nano-sized vesicles ( with a diameter in the range of 30 to 120 nm ) , that originate from the cell endocytic compartment through the formation of multivesicular bodies ( MVB ) , microvesicles , with a diameter up to 1 μm released by cell membrane budding , and apoptotic bodies , with a dimension similar to platelets , derived from blebbing of dying cells .
3-1	155-158	EVs	object	giv	coref	5-8[44_0]
3-2	159-162	can	_	_	_	_
3-3	163-165	be	_	_	_	_
3-4	166-176	classified	_	_	_	_
3-5	177-179	in	_	_	_	_
3-6	180-188	exosomes	object|object[10]	new|new[10]	coref|coref|coref|coref	5-14[45_0]|5-14[46_10]|5-14[45_0]|5-14[46_10]
3-7	189-190	,	object[10]	new[10]	_	_
3-8	191-201	nano-sized	object[10]|object[11]	new[10]|giv[11]	_	_
3-9	202-210	vesicles	object[10]|object[11]	new[10]|giv[11]	_	_
3-10	211-212	(	object[10]|object[11]	new[10]|giv[11]	_	_
3-11	213-217	with	object[10]|object[11]	new[10]|giv[11]	_	_
3-12	218-219	a	object[10]|object[11]|quantity[12]	new[10]|giv[11]|new[12]	coref	3-44[23_12]
3-13	220-228	diameter	object[10]|object[11]|quantity[12]	new[10]|giv[11]|new[12]	_	_
3-14	229-231	in	object[10]|object[11]|quantity[12]	new[10]|giv[11]|new[12]	_	_
3-15	232-235	the	object[10]|object[11]|quantity[12]|abstract[13]	new[10]|giv[11]|new[12]|new[13]	_	_
3-16	236-241	range	object[10]|object[11]|quantity[12]|abstract[13]	new[10]|giv[11]|new[12]|new[13]	_	_
3-17	242-244	of	object[10]|object[11]|quantity[12]|abstract[13]	new[10]|giv[11]|new[12]|new[13]	_	_
3-18	245-247	30	object[10]|object[11]|quantity[12]|abstract[13]|quantity	new[10]|giv[11]|new[12]|new[13]|new	_	_
3-19	248-250	to	object[10]|object[11]|quantity[12]|abstract[13]	new[10]|giv[11]|new[12]|new[13]	_	_
3-20	251-254	120	object[10]|object[11]|quantity[12]|abstract[13]|quantity[15]	new[10]|giv[11]|new[12]|new[13]|new[15]	_	_
3-21	255-257	nm	object[10]|object[11]|quantity[12]|abstract[13]|quantity[15]	new[10]|giv[11]|new[12]|new[13]|new[15]	_	_
3-22	258-259	)	object[10]|object[11]	new[10]|giv[11]	_	_
3-23	260-261	,	_	_	_	_
3-24	262-266	that	_	_	_	_
3-25	267-276	originate	_	_	_	_
3-26	277-281	from	_	_	_	_
3-27	282-285	the	place[18]	new[18]	_	_
3-28	286-290	cell	object|place[18]	new|new[18]	coref	13-24
3-29	291-300	endocytic	object|place[18]	new|new[18]	_	_
3-30	301-312	compartment	place[18]	new[18]	_	_
3-31	313-320	through	_	_	_	_
3-32	321-324	the	event[19]	new[19]	_	_
3-33	325-334	formation	event[19]	new[19]	_	_
3-34	335-337	of	event[19]	new[19]	_	_
3-35	338-352	multivesicular	event[19]|object[20]	new[19]|new[20]	appos	3-38[0_20]
3-36	353-359	bodies	event[19]|object[20]	new[19]|new[20]	_	_
3-37	360-361	(	_	_	_	_
3-38	362-365	MVB	object	giv	coref	3-57[27_0]
3-39	366-367	)	_	_	_	_
3-40	368-369	,	_	_	_	_
3-41	370-383	microvesicles	object[22]	new[22]	coref	5-17[0_22]
3-42	384-385	,	object[22]	new[22]	_	_
3-43	386-390	with	object[22]	new[22]	_	_
3-44	391-392	a	object[22]|quantity[23]	new[22]|giv[23]	_	_
3-45	393-401	diameter	object[22]|quantity[23]	new[22]|giv[23]	_	_
3-46	402-404	up	object[22]|quantity[23]	new[22]|giv[23]	_	_
3-47	405-407	to	object[22]|quantity[23]	new[22]|giv[23]	_	_
3-48	408-409	1	object[22]|quantity[23]|quantity[24]	new[22]|giv[23]|new[24]	_	_
3-49	410-412	μm	object[22]|quantity[23]|quantity[24]	new[22]|giv[23]|new[24]	_	_
3-50	413-421	released	_	_	_	_
3-51	422-424	by	_	_	_	_
3-52	425-429	cell	object[26]	new[26]	_	_
3-53	430-438	membrane	object|object[26]	giv|new[26]	coref	10-14[90_0]
3-54	439-446	budding	object[26]	new[26]	_	_
3-55	447-448	,	_	_	_	_
3-56	449-452	and	_	_	_	_
3-57	453-462	apoptotic	object[27]	giv[27]	_	_
3-58	463-469	bodies	object[27]	giv[27]	_	_
3-59	470-471	,	object[27]	giv[27]	_	_
3-60	472-476	with	object[27]	giv[27]	_	_
3-61	477-478	a	object[27]|abstract[28]	giv[27]|new[28]	ana	4-24[0_28]
3-62	479-488	dimension	object[27]|abstract[28]	giv[27]|new[28]	_	_
3-63	489-496	similar	object[27]|abstract[28]	giv[27]|new[28]	_	_
3-64	497-499	to	_	_	_	_
3-65	500-509	platelets	object	new	_	_
3-66	510-511	,	_	_	_	_
3-67	512-519	derived	_	_	_	_
3-68	520-524	from	_	_	_	_
3-69	525-533	blebbing	event[30]	new[30]	_	_
3-70	534-536	of	event[30]	new[30]	_	_
3-71	537-542	dying	event[30]|object[31]	new[30]|new[31]	coref	6-27[56_31]
3-72	543-548	cells	event[30]|object[31]	new[30]|new[31]	_	_
3-73	549-550	.	_	_	_	_

#Text=Despite the distinct sizes and biogenesis , the absence of standardized isolation methods and the numerous similarities existing between these two subclasses make it particularly challenging to distinguish among them .
4-1	551-558	Despite	_	_	_	_
4-2	559-562	the	quantity[32]	new[32]	_	_
4-3	563-571	distinct	quantity[32]	new[32]	_	_
4-4	572-577	sizes	quantity[32]	new[32]	_	_
4-5	578-581	and	_	_	_	_
4-6	582-592	biogenesis	abstract	new	_	_
4-7	593-594	,	_	_	_	_
4-8	595-598	the	abstract[34]	new[34]	_	_
4-9	599-606	absence	abstract[34]	new[34]	_	_
4-10	607-609	of	abstract[34]	new[34]	_	_
4-11	610-622	standardized	abstract[34]|abstract[36]	new[34]|new[36]	_	_
4-12	623-632	isolation	abstract[34]|abstract|abstract[36]	new[34]|new|new[36]	_	_
4-13	633-640	methods	abstract[34]|abstract[36]	new[34]|new[36]	_	_
4-14	641-644	and	_	_	_	_
4-15	645-648	the	abstract[37]	new[37]	_	_
4-16	649-657	numerous	abstract[37]	new[37]	_	_
4-17	658-670	similarities	abstract[37]	new[37]	_	_
4-18	671-679	existing	_	_	_	_
4-19	680-687	between	_	_	_	_
4-20	688-693	these	abstract[38]	new[38]	ana	4-30[0_38]
4-21	694-697	two	abstract[38]	new[38]	_	_
4-22	698-708	subclasses	abstract[38]	new[38]	_	_
4-23	709-713	make	_	_	_	_
4-24	714-716	it	abstract	giv	_	_
4-25	717-729	particularly	_	_	_	_
4-26	730-741	challenging	_	_	_	_
4-27	742-744	to	_	_	_	_
4-28	745-756	distinguish	_	_	_	_
4-29	757-762	among	_	_	_	_
4-30	763-767	them	abstract	giv	_	_
4-31	768-769	.	_	_	_	_

#Text=In this review , we will use the generic term EVs to indicate both exosomes and microvesicles .
5-1	770-772	In	_	_	_	_
5-2	773-777	this	abstract[41]	new[41]	coref	21-7[191_41]
5-3	778-784	review	abstract[41]	new[41]	_	_
5-4	785-786	,	_	_	_	_
5-5	787-789	we	person	acc	ana	22-9
5-6	790-794	will	_	_	_	_
5-7	795-798	use	_	_	_	_
5-8	799-802	the	abstract[44]	giv[44]	coref	6-1[0_44]
5-9	803-810	generic	abstract[44]	giv[44]	_	_
5-10	811-815	term	abstract|abstract[44]	new|giv[44]	_	_
5-11	816-819	EVs	abstract[44]	giv[44]	_	_
5-12	820-822	to	_	_	_	_
5-13	823-831	indicate	_	_	_	_
5-14	832-836	both	object[45]|object[46]	giv[45]|giv[46]	_	_
5-15	837-845	exosomes	object[45]|object[46]	giv[45]|giv[46]	_	_
5-16	846-849	and	object[46]	giv[46]	_	_
5-17	850-863	microvesicles	object[46]|object	giv[46]|giv	_	_
5-18	864-865	.	_	_	_	_

#Text=EVs have been shown to carry functionally active biological materials including proteins , mRNAs and miRNAs , which makes them capable of transmitting signals to target cells in the surrounding environment as well as to distant organs , via blood and lymphatic vessels .
6-1	866-869	EVs	abstract	giv	coref	7-13
6-2	870-874	have	_	_	_	_
6-3	875-879	been	_	_	_	_
6-4	880-885	shown	_	_	_	_
6-5	886-888	to	_	_	_	_
6-6	889-894	carry	_	_	_	_
6-7	895-907	functionally	substance[49]	new[49]	_	_
6-8	908-914	active	substance[49]	new[49]	_	_
6-9	915-925	biological	substance[49]	new[49]	_	_
6-10	926-935	materials	substance[49]	new[49]	_	_
6-11	936-945	including	substance[49]	new[49]	_	_
6-12	946-954	proteins	substance[49]|substance|abstract[51]	new[49]|new|new[51]	ana|coref|ana|coref	6-20[0_51]|13-16[121_0]|6-20[0_51]|13-16[121_0]
6-13	955-956	,	substance[49]|abstract[51]	new[49]|new[51]	_	_
6-14	957-962	mRNAs	substance[49]|abstract[51]|object	new[49]|new[51]|new	_	_
6-15	963-966	and	substance[49]|abstract[51]	new[49]|new[51]	_	_
6-16	967-973	miRNAs	substance[49]|abstract[51]|person	new[49]|new[51]|new	_	_
6-17	974-975	,	_	_	_	_
6-18	976-981	which	_	_	_	_
6-19	982-987	makes	_	_	_	_
6-20	988-992	them	abstract	giv	_	_
6-21	993-1000	capable	_	_	_	_
6-22	1001-1003	of	_	_	_	_
6-23	1004-1016	transmitting	_	_	_	_
6-24	1017-1024	signals	abstract	new	_	_
6-25	1025-1027	to	_	_	_	_
6-26	1028-1034	target	abstract	new	coref|none	21-36[199_0]|6-26[0_199]
6-27	1035-1040	cells	object[56]	giv[56]	coref	9-11[80_56]
6-28	1041-1043	in	object[56]	giv[56]	_	_
6-29	1044-1047	the	object[56]|place[57]	giv[56]|new[57]	_	_
6-30	1048-1059	surrounding	object[56]|place[57]	giv[56]|new[57]	_	_
6-31	1060-1071	environment	object[56]|place[57]	giv[56]|new[57]	_	_
6-32	1072-1074	as	object[56]	giv[56]	_	_
6-33	1075-1079	well	object[56]	giv[56]	_	_
6-34	1080-1082	as	object[56]	giv[56]	_	_
6-35	1083-1085	to	object[56]	giv[56]	_	_
6-36	1086-1093	distant	object[56]|object[58]	giv[56]|new[58]	coref	19-24[181_58]
6-37	1094-1100	organs	object[56]|object[58]	giv[56]|new[58]	_	_
6-38	1101-1102	,	object[56]|object[58]	giv[56]|new[58]	_	_
6-39	1103-1106	via	object[56]|object[58]	giv[56]|new[58]	_	_
6-40	1107-1112	blood	object[56]|object[58]|substance|object[60]	giv[56]|new[58]|new|new[60]	coref|coref|coref|coref	9-16|11-21[111_60]|9-16|11-21[111_60]
6-41	1113-1116	and	object[56]|object[58]|object[60]	giv[56]|new[58]|new[60]	_	_
6-42	1117-1126	lymphatic	object[56]|object[58]|object[60]	giv[56]|new[58]|new[60]	_	_
6-43	1127-1134	vessels	object[56]|object[58]|object[60]	giv[56]|new[58]|new[60]	_	_
6-44	1135-1136	.	_	_	_	_

#Text=The scientific community has recently turned its interest toward the evaluation of EVs as drug delivery vehicles .
7-1	1137-1140	The	organization[61]	new[61]	ana	7-7[0_61]
7-2	1141-1151	scientific	organization[61]	new[61]	_	_
7-3	1152-1161	community	organization[61]	new[61]	_	_
7-4	1162-1165	has	_	_	_	_
7-5	1166-1174	recently	_	_	_	_
7-6	1175-1181	turned	_	_	_	_
7-7	1182-1185	its	organization|abstract[63]	giv|new[63]	coref|coref|coref|coref	20-11[186_0]|20-10[187_63]|20-11[186_0]|20-10[187_63]
7-8	1186-1194	interest	abstract[63]	new[63]	_	_
7-9	1195-1201	toward	_	_	_	_
7-10	1202-1205	the	abstract[64]	new[64]	_	_
7-11	1206-1216	evaluation	abstract[64]	new[64]	_	_
7-12	1217-1219	of	abstract[64]	new[64]	_	_
7-13	1220-1223	EVs	abstract[64]|abstract	new[64]|giv	coref	8-5
7-14	1224-1226	as	abstract[64]	new[64]	_	_
7-15	1227-1231	drug	abstract[64]|substance	new[64]|new	coref	8-11
7-16	1232-1240	delivery	abstract[64]|abstract	new[64]|new	coref	8-12
7-17	1241-1249	vehicles	abstract[64]	new[64]	_	_
7-18	1250-1251	.	_	_	_	_

#Text=In this context , EVs offer significant advantages over current drug delivery systems , such as liposomes and polymeric nanoparticles .
8-1	1252-1254	In	_	_	_	_
8-2	1255-1259	this	abstract[68]	new[68]	_	_
8-3	1260-1267	context	abstract[68]	new[68]	_	_
8-4	1268-1269	,	_	_	_	_
8-5	1270-1273	EVs	abstract	giv	coref	9-2
8-6	1274-1279	offer	_	_	_	_
8-7	1280-1291	significant	abstract[70]	new[70]	_	_
8-8	1292-1302	advantages	abstract[70]	new[70]	_	_
8-9	1303-1307	over	abstract[70]	new[70]	_	_
8-10	1308-1315	current	abstract[70]|abstract[73]	new[70]|new[73]	coref	14-6[134_73]
8-11	1316-1320	drug	abstract[70]|substance|abstract[73]	new[70]|giv|new[73]	coref	10-26[92_0]
8-12	1321-1329	delivery	abstract[70]|abstract|abstract[73]	new[70]|giv|new[73]	coref	14-8
8-13	1330-1337	systems	abstract[70]|abstract[73]	new[70]|new[73]	_	_
8-14	1338-1339	,	abstract[70]|abstract[73]	new[70]|new[73]	_	_
8-15	1340-1344	such	abstract[70]|abstract[73]	new[70]|new[73]	_	_
8-16	1345-1347	as	abstract[70]|abstract[73]	new[70]|new[73]	_	_
8-17	1348-1357	liposomes	abstract[70]|abstract[73]|object	new[70]|new[73]|new	coref	14-2[135_0]
8-18	1358-1361	and	abstract[70]|abstract[73]	new[70]|new[73]	_	_
8-19	1362-1371	polymeric	abstract[70]|abstract[73]|object[75]	new[70]|new[73]|new[75]	coref	13-42[130_75]
8-20	1372-1385	nanoparticles	abstract[70]|abstract[73]|object[75]	new[70]|new[73]|new[75]	_	_
8-21	1386-1387	.	_	_	_	_

#Text=Since EVs can be obtained with an autologous procedure from the patient ’s cells or blood , they do not solicit the immune system as usual synthetic formulations do .
9-1	1388-1393	Since	_	_	_	_
9-2	1394-1397	EVs	abstract	giv	coref	10-9
9-3	1398-1401	can	_	_	_	_
9-4	1402-1404	be	_	_	_	_
9-5	1405-1413	obtained	_	_	_	_
9-6	1414-1418	with	_	_	_	_
9-7	1419-1421	an	abstract[78]	new[78]	_	_
9-8	1422-1432	autologous	person|abstract[78]	new|new[78]	_	_
9-9	1433-1442	procedure	abstract[78]	new[78]	_	_
9-10	1443-1447	from	abstract[78]	new[78]	_	_
9-11	1448-1451	the	abstract[78]|object[80]	new[78]|giv[80]	ana	9-18[0_80]
9-12	1452-1459	patient	abstract[78]|person[79]|object[80]	new[78]|new[79]|giv[80]	_	_
9-13	1460-1462	’s	abstract[78]|person[79]|object[80]	new[78]|new[79]|giv[80]	_	_
9-14	1463-1468	cells	abstract[78]|object[80]	new[78]|giv[80]	_	_
9-15	1469-1471	or	abstract[78]|object[80]	new[78]|giv[80]	_	_
9-16	1472-1477	blood	abstract[78]|object[80]|substance	new[78]|giv[80]|giv	_	_
9-17	1478-1479	,	_	_	_	_
9-18	1480-1484	they	object	giv	_	_
9-19	1485-1487	do	_	_	_	_
9-20	1488-1491	not	_	_	_	_
9-21	1492-1499	solicit	_	_	_	_
9-22	1500-1503	the	place[83]	new[83]	coref	10-59[104_83]
9-23	1504-1510	immune	place[83]	new[83]	_	_
9-24	1511-1517	system	place[83]	new[83]	_	_
9-25	1518-1520	as	_	_	_	_
9-26	1521-1526	usual	object[84]	new[84]	ana	10-5[0_84]
9-27	1527-1536	synthetic	object[84]	new[84]	_	_
9-28	1537-1549	formulations	object[84]	new[84]	_	_
9-29	1550-1552	do	_	_	_	_
9-30	1553-1554	.	_	_	_	_

#Text=In addition , given their phospholipid bilayer , EVs can directly fuse with the targeted plasma membrane , thus allowing a more efficient internalization of the encapsulated drug . Their hydrophilic shell , together with the presence of anti-phagocytosis surface markers ( i. e. , CD47 ) , enables them to evade phagocytosis by monocytes and macrophages of the reticulo-endothelial system , hence weakening their clearance .
10-1	1555-1557	In	_	_	_	_
10-2	1558-1566	addition	_	_	_	_
10-3	1567-1568	,	_	_	_	_
10-4	1569-1574	given	_	_	_	_
10-5	1575-1580	their	object|object[87]	giv|new[87]	ana|ana	10-30|10-30
10-6	1581-1593	phospholipid	person|object[87]	new|new[87]	_	_
10-7	1594-1601	bilayer	object[87]	new[87]	_	_
10-8	1602-1603	,	_	_	_	_
10-9	1604-1607	EVs	abstract	giv	coref	16-17
10-10	1608-1611	can	_	_	_	_
10-11	1612-1620	directly	_	_	_	_
10-12	1621-1625	fuse	_	_	_	_
10-13	1626-1630	with	_	_	_	_
10-14	1631-1634	the	object[90]	giv[90]	coref	13-8[0_90]
10-15	1635-1643	targeted	object[90]	giv[90]	_	_
10-16	1644-1650	plasma	abstract|object[90]	new|giv[90]	_	_
10-17	1651-1659	membrane	object[90]	giv[90]	_	_
10-18	1660-1661	,	_	_	_	_
10-19	1662-1666	thus	_	_	_	_
10-20	1667-1675	allowing	_	_	_	_
10-21	1676-1677	a	abstract[91]	new[91]	_	_
10-22	1678-1682	more	abstract[91]	new[91]	_	_
10-23	1683-1692	efficient	abstract[91]	new[91]	_	_
10-24	1693-1708	internalization	abstract[91]	new[91]	_	_
10-25	1709-1711	of	abstract[91]	new[91]	_	_
10-26	1712-1715	the	abstract[91]|substance[92]	new[91]|giv[92]	coref	14-7[0_92]
10-27	1716-1728	encapsulated	abstract[91]|substance[92]	new[91]|giv[92]	_	_
10-28	1729-1733	drug	abstract[91]|substance[92]	new[91]|giv[92]	_	_
10-29	1734-1735	.	_	_	_	_
10-30	1736-1741	Their	object|object[94]	giv|new[94]	ana|ana	10-50|10-50
10-31	1742-1753	hydrophilic	object[94]	new[94]	_	_
10-32	1754-1759	shell	object[94]	new[94]	_	_
10-33	1760-1761	,	_	_	_	_
10-34	1762-1770	together	abstract[95]	new[95]	_	_
10-35	1771-1775	with	abstract[95]	new[95]	_	_
10-36	1776-1779	the	abstract[95]	new[95]	_	_
10-37	1780-1788	presence	abstract[95]	new[95]	_	_
10-38	1789-1791	of	abstract[95]	new[95]	_	_
10-39	1792-1809	anti-phagocytosis	abstract[95]|place|abstract[98]	new[95]|new|new[98]	_	_
10-40	1810-1817	surface	abstract[95]|place|abstract[98]	new[95]|new|new[98]	_	_
10-41	1818-1825	markers	abstract[95]|abstract[98]	new[95]|new[98]	_	_
10-42	1826-1827	(	_	_	_	_
10-43	1828-1830	i.	_	_	_	_
10-44	1831-1833	e.	_	_	_	_
10-45	1834-1835	,	_	_	_	_
10-46	1836-1840	CD47	object	new	_	_
10-47	1841-1842	)	_	_	_	_
10-48	1843-1844	,	_	_	_	_
10-49	1845-1852	enables	_	_	_	_
10-50	1853-1857	them	object	giv	ana	10-65
10-51	1858-1860	to	_	_	_	_
10-52	1861-1866	evade	_	_	_	_
10-53	1867-1879	phagocytosis	abstract	new	_	_
10-54	1880-1882	by	_	_	_	_
10-55	1883-1892	monocytes	object	new	_	_
10-56	1893-1896	and	_	_	_	_
10-57	1897-1908	macrophages	object[103]	new[103]	_	_
10-58	1909-1911	of	object[103]	new[103]	_	_
10-59	1912-1915	the	object[103]|place[104]	new[103]|giv[104]	_	_
10-60	1916-1936	reticulo-endothelial	object[103]|place[104]	new[103]|giv[104]	_	_
10-61	1937-1943	system	object[103]|place[104]	new[103]|giv[104]	_	_
10-62	1944-1945	,	_	_	_	_
10-63	1946-1951	hence	_	_	_	_
10-64	1952-1961	weakening	_	_	_	_
10-65	1962-1967	their	object|abstract[106]	giv|new[106]	ana|ana	11-7|11-7
10-66	1968-1977	clearance	abstract[106]	new[106]	_	_
10-67	1978-1979	.	_	_	_	_

#Text=Moreover , the limited size allows them to efficiently extravasate through the inter-endothelial junctions and fenestrations of both existing and neo-synthesized vessels .
11-1	1980-1988	Moreover	_	_	_	_
11-2	1989-1990	,	_	_	_	_
11-3	1991-1994	the	quantity[107]	new[107]	_	_
11-4	1995-2002	limited	quantity[107]	new[107]	_	_
11-5	2003-2007	size	quantity[107]	new[107]	_	_
11-6	2008-2014	allows	_	_	_	_
11-7	2015-2019	them	object	giv	coref	15-17[143_0]
11-8	2020-2022	to	_	_	_	_
11-9	2023-2034	efficiently	_	_	_	_
11-10	2035-2046	extravasate	_	_	_	_
11-11	2047-2054	through	_	_	_	_
11-12	2055-2058	the	place[109]	new[109]	_	_
11-13	2059-2076	inter-endothelial	place[109]	new[109]	_	_
11-14	2077-2086	junctions	place[109]	new[109]	_	_
11-15	2087-2090	and	_	_	_	_
11-16	2091-2104	fenestrations	abstract[110]	new[110]	_	_
11-17	2105-2107	of	abstract[110]	new[110]	_	_
11-18	2108-2112	both	abstract[110]	new[110]	_	_
11-19	2113-2121	existing	abstract[110]	new[110]	_	_
11-20	2122-2125	and	abstract[110]	new[110]	_	_
11-21	2126-2141	neo-synthesized	abstract[110]|object[111]	new[110]|giv[111]	_	_
11-22	2142-2149	vessels	abstract[110]|object[111]	new[110]|giv[111]	_	_
11-23	2150-2151	.	_	_	_	_

#Text=Thanks to these peculiar characteristics , they can spread and accumulate in the parenchyma of solid tumors .
12-1	2152-2158	Thanks	_	_	_	_
12-2	2159-2161	to	_	_	_	_
12-3	2162-2167	these	abstract[112]	new[112]	ana	12-7[0_112]
12-4	2168-2176	peculiar	abstract[112]	new[112]	_	_
12-5	2177-2192	characteristics	abstract[112]	new[112]	_	_
12-6	2193-2194	,	_	_	_	_
12-7	2195-2199	they	abstract	giv	_	_
12-8	2200-2203	can	_	_	_	_
12-9	2204-2210	spread	_	_	_	_
12-10	2211-2214	and	_	_	_	_
12-11	2215-2225	accumulate	_	_	_	_
12-12	2226-2228	in	_	_	_	_
12-13	2229-2232	the	place[114]	new[114]	_	_
12-14	2233-2243	parenchyma	place[114]	new[114]	_	_
12-15	2244-2246	of	place[114]	new[114]	_	_
12-16	2247-2252	solid	place[114]|object[115]	new[114]|new[115]	_	_
12-17	2253-2259	tumors	place[114]|object[115]	new[114]|new[115]	_	_
12-18	2260-2261	.	_	_	_	_

#Text=EV biological properties derive from their sophisticated membrane structure , characterized by the presence of several proteins for active targeting , adhesion , cell fusion , and intracellular release of their content ; this functional complexity is not easily reproduced by de novo synthesized nanoparticles .
13-1	2262-2264	EV	abstract[116]	new[116]	ana	13-6[0_116]
13-2	2265-2275	biological	abstract[116]	new[116]	_	_
13-3	2276-2286	properties	abstract[116]	new[116]	_	_
13-4	2287-2293	derive	_	_	_	_
13-5	2294-2298	from	_	_	_	_
13-6	2299-2304	their	abstract|abstract[119]	giv|new[119]	ana|ana	13-31|13-31
13-7	2305-2318	sophisticated	abstract[119]	new[119]	_	_
13-8	2319-2327	membrane	object|abstract[119]	giv|new[119]	_	_
13-9	2328-2337	structure	abstract[119]	new[119]	_	_
13-10	2338-2339	,	_	_	_	_
13-11	2340-2353	characterized	_	_	_	_
13-12	2354-2356	by	_	_	_	_
13-13	2357-2360	the	abstract[120]	new[120]	_	_
13-14	2361-2369	presence	abstract[120]	new[120]	_	_
13-15	2370-2372	of	abstract[120]	new[120]	_	_
13-16	2373-2380	several	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-17	2381-2389	proteins	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-18	2390-2393	for	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-19	2394-2400	active	abstract[120]|substance[121]|event[122]	new[120]|giv[121]|new[122]	_	_
13-20	2401-2410	targeting	abstract[120]|substance[121]|event[122]	new[120]|giv[121]|new[122]	_	_
13-21	2411-2412	,	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-22	2413-2421	adhesion	abstract[120]|substance[121]|abstract	new[120]|giv[121]|new	_	_
13-23	2422-2423	,	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-24	2424-2428	cell	abstract[120]|substance[121]|place|event[125]	new[120]|giv[121]|giv|new[125]	_	_
13-25	2429-2435	fusion	abstract[120]|substance[121]|event[125]	new[120]|giv[121]|new[125]	_	_
13-26	2436-2437	,	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-27	2438-2441	and	abstract[120]|substance[121]	new[120]|giv[121]	_	_
13-28	2442-2455	intracellular	abstract[120]|substance[121]|event[126]	new[120]|giv[121]|new[126]	_	_
13-29	2456-2463	release	abstract[120]|substance[121]|event[126]	new[120]|giv[121]|new[126]	_	_
13-30	2464-2466	of	abstract[120]|substance[121]|event[126]	new[120]|giv[121]|new[126]	_	_
13-31	2467-2472	their	abstract[120]|substance[121]|event[126]|abstract|abstract[128]	new[120]|giv[121]|new[126]|giv|new[128]	_	_
13-32	2473-2480	content	abstract[120]|substance[121]|event[126]|abstract[128]	new[120]|giv[121]|new[126]|new[128]	_	_
13-33	2481-2482	;	_	_	_	_
13-34	2483-2487	this	abstract[129]	new[129]	_	_
13-35	2488-2498	functional	abstract[129]	new[129]	_	_
13-36	2499-2509	complexity	abstract[129]	new[129]	_	_
13-37	2510-2512	is	_	_	_	_
13-38	2513-2516	not	_	_	_	_
13-39	2517-2523	easily	_	_	_	_
13-40	2524-2534	reproduced	_	_	_	_
13-41	2535-2537	by	_	_	_	_
13-42	2538-2540	de	object[130]	giv[130]	_	_
13-43	2541-2545	novo	object[130]	giv[130]	_	_
13-44	2546-2557	synthesized	object[130]	giv[130]	_	_
13-45	2558-2571	nanoparticles	object[130]	giv[130]	_	_
13-46	2572-2573	.	_	_	_	_

#Text=Among the several types of nano-based drug delivery systems , liposomes are probably the most used , due to their non-toxicity and capacity to accommodate high amounts of compounds .
14-1	2574-2579	Among	_	_	_	_
14-2	2580-2583	the	abstract[131]|object[135]	new[131]|giv[135]	ana|ana	14-20[0_135]|14-20[0_135]
14-3	2584-2591	several	abstract[131]|object[135]	new[131]|giv[135]	_	_
14-4	2592-2597	types	abstract[131]|object[135]	new[131]|giv[135]	_	_
14-5	2598-2600	of	abstract[131]|object[135]	new[131]|giv[135]	_	_
14-6	2601-2611	nano-based	abstract[131]|abstract[134]|object[135]	new[131]|giv[134]|giv[135]	_	_
14-7	2612-2616	drug	abstract[131]|substance|abstract[134]|object[135]	new[131]|giv|giv[134]|giv[135]	coref	16-21
14-8	2617-2625	delivery	abstract[131]|abstract|abstract[134]|object[135]	new[131]|giv|giv[134]|giv[135]	coref	16-21[153_0]
14-9	2626-2633	systems	abstract[131]|abstract[134]|object[135]	new[131]|giv[134]|giv[135]	_	_
14-10	2634-2635	,	object[135]	giv[135]	_	_
14-11	2636-2645	liposomes	object[135]	giv[135]	_	_
14-12	2646-2649	are	_	_	_	_
14-13	2650-2658	probably	_	_	_	_
14-14	2659-2662	the	_	_	_	_
14-15	2663-2667	most	_	_	_	_
14-16	2668-2672	used	_	_	_	_
14-17	2673-2674	,	_	_	_	_
14-18	2675-2678	due	_	_	_	_
14-19	2679-2681	to	_	_	_	_
14-20	2682-2687	their	object	giv	_	_
14-21	2688-2700	non-toxicity	_	_	_	_
14-22	2701-2704	and	_	_	_	_
14-23	2705-2713	capacity	abstract	new	_	_
14-24	2714-2716	to	_	_	_	_
14-25	2717-2728	accommodate	_	_	_	_
14-26	2729-2733	high	object[138]	new[138]	_	_
14-27	2734-2741	amounts	object[138]	new[138]	_	_
14-28	2742-2744	of	object[138]	new[138]	_	_
14-29	2745-2754	compounds	object[138]|substance	new[138]|new	_	_
14-30	2755-2756	.	_	_	_	_

#Text=However , a still inadequate in vivo targeting efficiency together with a potential immunogenicity associated to liposomal formulations has limited their broad applicability in therapeutics .
15-1	2757-2764	However	_	_	_	_
15-2	2765-2766	,	_	_	_	_
15-3	2767-2768	a	_	_	_	_
15-4	2769-2774	still	_	_	_	_
15-5	2775-2785	inadequate	_	_	_	_
15-6	2786-2788	in	_	_	_	_
15-7	2789-2793	vivo	_	_	_	_
15-8	2794-2803	targeting	_	_	_	_
15-9	2804-2814	efficiency	abstract[140]	new[140]	_	_
15-10	2815-2823	together	abstract[140]	new[140]	_	_
15-11	2824-2828	with	abstract[140]	new[140]	_	_
15-12	2829-2830	a	abstract[140]|abstract[141]	new[140]|new[141]	_	_
15-13	2831-2840	potential	abstract[140]|abstract[141]	new[140]|new[141]	_	_
15-14	2841-2855	immunogenicity	abstract[140]|abstract[141]	new[140]|new[141]	_	_
15-15	2856-2866	associated	_	_	_	_
15-16	2867-2869	to	_	_	_	_
15-17	2870-2879	liposomal	animal|object[143]	new|giv[143]	ana|ana	15-21[0_143]|15-21[0_143]
15-18	2880-2892	formulations	object[143]	giv[143]	_	_
15-19	2893-2896	has	_	_	_	_
15-20	2897-2904	limited	_	_	_	_
15-21	2905-2910	their	object|abstract[145]	giv|new[145]	coref|coref	18-14[168_0]|18-14[168_0]
15-22	2911-2916	broad	abstract[145]	new[145]	_	_
15-23	2917-2930	applicability	abstract[145]	new[145]	_	_
15-24	2931-2933	in	abstract[145]	new[145]	_	_
15-25	2934-2946	therapeutics	abstract[145]|abstract	new[145]|new	_	_
15-26	2947-2948	.	_	_	_	_

#Text=Therefore , the greater specificity combined with the consequent limited induction of systemic side effects make EVs ideal vehicles for drug delivery .
16-1	2949-2958	Therefore	_	_	_	_
16-2	2959-2960	,	_	_	_	_
16-3	2961-2964	the	abstract[147]	new[147]	_	_
16-4	2965-2972	greater	abstract[147]	new[147]	_	_
16-5	2973-2984	specificity	abstract[147]	new[147]	_	_
16-6	2985-2993	combined	_	_	_	_
16-7	2994-2998	with	_	_	_	_
16-8	2999-3002	the	abstract[148]	new[148]	_	_
16-9	3003-3013	consequent	abstract[148]	new[148]	_	_
16-10	3014-3021	limited	abstract[148]	new[148]	_	_
16-11	3022-3031	induction	abstract[148]	new[148]	_	_
16-12	3032-3034	of	abstract[148]	new[148]	_	_
16-13	3035-3043	systemic	abstract[148]|abstract[149]	new[148]|new[149]	coref	19-29[182_149]
16-14	3044-3048	side	abstract[148]|abstract[149]	new[148]|new[149]	_	_
16-15	3049-3056	effects	abstract[148]|abstract[149]	new[148]|new[149]	_	_
16-16	3057-3061	make	_	_	_	_
16-17	3062-3065	EVs	abstract|object[151]	giv|new[151]	coref|coref	17-18[160_0]|17-18[160_0]
16-18	3066-3071	ideal	object[151]	new[151]	_	_
16-19	3072-3080	vehicles	object[151]	new[151]	_	_
16-20	3081-3084	for	object[151]	new[151]	_	_
16-21	3085-3089	drug	object[151]|substance|abstract[153]	new[151]|giv|giv[153]	ana|coref|ana|coref	17-7[0_153]|19-21|17-7[0_153]|19-21
16-22	3090-3098	delivery	object[151]|abstract[153]	new[151]|giv[153]	_	_
16-23	3099-3100	.	_	_	_	_

#Text=Although this research field is in its infancy , in the last decade , the use of bio-engineered EVs for the delivery of cytotoxic molecules in preclinical models has produced encouraging results .
17-1	3101-3109	Although	_	_	_	_
17-2	3110-3114	this	abstract[155]	new[155]	coref	20-17[189_155]
17-3	3115-3123	research	abstract|abstract[155]	new|new[155]	coref	20-19
17-4	3124-3129	field	abstract[155]	new[155]	_	_
17-5	3130-3132	is	_	_	_	_
17-6	3133-3135	in	_	_	_	_
17-7	3136-3139	its	abstract|time[157]	giv|new[157]	coref|coref	17-21[161_0]|17-21[161_0]
17-8	3140-3147	infancy	time[157]	new[157]	_	_
17-9	3148-3149	,	time[157]	new[157]	_	_
17-10	3150-3152	in	time[157]	new[157]	_	_
17-11	3153-3156	the	time[157]|time[158]	new[157]|new[158]	_	_
17-12	3157-3161	last	time[157]|time[158]	new[157]|new[158]	_	_
17-13	3162-3168	decade	time[157]|time[158]	new[157]|new[158]	_	_
17-14	3169-3170	,	_	_	_	_
17-15	3171-3174	the	abstract[159]	new[159]	_	_
17-16	3175-3178	use	abstract[159]	new[159]	_	_
17-17	3179-3181	of	abstract[159]	new[159]	_	_
17-18	3182-3196	bio-engineered	abstract[159]|abstract[160]	new[159]|giv[160]	coref	21-19[0_160]
17-19	3197-3200	EVs	abstract[159]|abstract[160]	new[159]|giv[160]	_	_
17-20	3201-3204	for	abstract[159]	new[159]	_	_
17-21	3205-3208	the	abstract[159]|abstract[161]	new[159]|giv[161]	coref	21-22[0_161]
17-22	3209-3217	delivery	abstract[159]|abstract[161]	new[159]|giv[161]	_	_
17-23	3218-3220	of	abstract[159]|abstract[161]	new[159]|giv[161]	_	_
17-24	3221-3230	cytotoxic	abstract[159]|abstract[161]|object[162]	new[159]|giv[161]|new[162]	coref	21-31[198_162]
17-25	3231-3240	molecules	abstract[159]|abstract[161]|object[162]	new[159]|giv[161]|new[162]	_	_
17-26	3241-3243	in	abstract[159]|abstract[161]|object[162]	new[159]|giv[161]|new[162]	_	_
17-27	3244-3255	preclinical	abstract[159]|abstract[161]|object[162]|abstract[163]	new[159]|giv[161]|new[162]|new[163]	_	_
17-28	3256-3262	models	abstract[159]|abstract[161]|object[162]|abstract[163]	new[159]|giv[161]|new[162]|new[163]	_	_
17-29	3263-3266	has	_	_	_	_
17-30	3267-3275	produced	_	_	_	_
17-31	3276-3287	encouraging	_	_	_	_
17-32	3288-3295	results	abstract	new	_	_
17-33	3296-3297	.	_	_	_	_

#Text=These experimental evidences , in addition to preliminary clinical data , indicate that EV formulations may not only enhance the safety and biodistribution of commonly used drugs , but also increase their efficacy .
18-1	3298-3303	These	abstract[165]	new[165]	_	_
18-2	3304-3316	experimental	abstract[165]	new[165]	_	_
18-3	3317-3326	evidences	abstract[165]	new[165]	_	_
18-4	3327-3328	,	abstract[165]	new[165]	_	_
18-5	3329-3331	in	abstract[165]	new[165]	_	_
18-6	3332-3340	addition	abstract[165]	new[165]	_	_
18-7	3341-3343	to	abstract[165]	new[165]	_	_
18-8	3344-3355	preliminary	abstract[165]|abstract[166]	new[165]|new[166]	_	_
18-9	3356-3364	clinical	abstract[165]|abstract[166]	new[165]|new[166]	_	_
18-10	3365-3369	data	abstract[165]|abstract[166]	new[165]|new[166]	_	_
18-11	3370-3371	,	_	_	_	_
18-12	3372-3380	indicate	_	_	_	_
18-13	3381-3385	that	_	_	_	_
18-14	3386-3388	EV	abstract|object[168]	new|giv[168]	_	_
18-15	3389-3401	formulations	object[168]	giv[168]	_	_
18-16	3402-3405	may	_	_	_	_
18-17	3406-3409	not	_	_	_	_
18-18	3410-3414	only	_	_	_	_
18-19	3415-3422	enhance	_	_	_	_
18-20	3423-3426	the	abstract[169]	new[169]	_	_
18-21	3427-3433	safety	abstract[169]	new[169]	_	_
18-22	3434-3437	and	_	_	_	_
18-23	3438-3453	biodistribution	substance[170]	new[170]	_	_
18-24	3454-3456	of	substance[170]	new[170]	_	_
18-25	3457-3465	commonly	substance[170]|substance[171]	new[170]|new[171]	ana	18-32[0_171]
18-26	3466-3470	used	substance[170]|substance[171]	new[170]|new[171]	_	_
18-27	3471-3476	drugs	substance[170]|substance[171]	new[170]|new[171]	_	_
18-28	3477-3478	,	_	_	_	_
18-29	3479-3482	but	_	_	_	_
18-30	3483-3487	also	_	_	_	_
18-31	3488-3496	increase	_	_	_	_
18-32	3497-3502	their	substance|abstract[173]	giv|new[173]	ana|coref|ana|coref	19-4[0_173]|19-12[177_0]|19-4[0_173]|19-12[177_0]
18-33	3503-3511	efficacy	abstract[173]	new[173]	_	_
18-34	3512-3513	.	_	_	_	_

#Text=For example , it has been demonstrated that the administration of EV-encapsulating chemotherapy drugs leads to a significant reduction of drug accumulation in off-target organs , thus preventing important side effects during standard clinical protocols .
19-1	3514-3517	For	_	_	_	_
19-2	3518-3525	example	_	_	_	_
19-3	3526-3527	,	_	_	_	_
19-4	3528-3530	it	abstract	giv	_	_
19-5	3531-3534	has	_	_	_	_
19-6	3535-3539	been	_	_	_	_
19-7	3540-3552	demonstrated	_	_	_	_
19-8	3553-3557	that	_	_	_	_
19-9	3558-3561	the	event[175]	new[175]	_	_
19-10	3562-3576	administration	event[175]	new[175]	_	_
19-11	3577-3579	of	event[175]	new[175]	_	_
19-12	3580-3596	EV-encapsulating	event[175]|substance[177]	new[175]|giv[177]	_	_
19-13	3597-3609	chemotherapy	event[175]|abstract|substance[177]	new[175]|new|giv[177]	_	_
19-14	3610-3615	drugs	event[175]|substance[177]	new[175]|giv[177]	_	_
19-15	3616-3621	leads	_	_	_	_
19-16	3622-3624	to	_	_	_	_
19-17	3625-3626	a	abstract[178]	new[178]	_	_
19-18	3627-3638	significant	abstract[178]	new[178]	_	_
19-19	3639-3648	reduction	abstract[178]	new[178]	_	_
19-20	3649-3651	of	abstract[178]	new[178]	_	_
19-21	3652-3656	drug	abstract[178]|substance|abstract[180]	new[178]|giv|new[180]	coref|coref	21-21|21-21
19-22	3657-3669	accumulation	abstract[178]|abstract[180]	new[178]|new[180]	_	_
19-23	3670-3672	in	abstract[178]|abstract[180]	new[178]|new[180]	_	_
19-24	3673-3683	off-target	abstract[178]|abstract[180]|object[181]	new[178]|new[180]|giv[181]	_	_
19-25	3684-3690	organs	abstract[178]|abstract[180]|object[181]	new[178]|new[180]|giv[181]	_	_
19-26	3691-3692	,	_	_	_	_
19-27	3693-3697	thus	_	_	_	_
19-28	3698-3708	preventing	_	_	_	_
19-29	3709-3718	important	abstract[182]	giv[182]	_	_
19-30	3719-3723	side	abstract[182]	giv[182]	_	_
19-31	3724-3731	effects	abstract[182]	giv[182]	_	_
19-32	3732-3738	during	_	_	_	_
19-33	3739-3747	standard	event[183]	new[183]	_	_
19-34	3748-3756	clinical	event[183]	new[183]	_	_
19-35	3757-3766	protocols	event[183]	new[183]	_	_
19-36	3767-3768	.	_	_	_	_

#Text=An astonishing number of newly published papers perfectly depict the scientific community ’s authentic interest in this flourishing research field .
20-1	3769-3771	An	abstract[184]	new[184]	_	_
20-2	3772-3783	astonishing	abstract[184]	new[184]	_	_
20-3	3784-3790	number	abstract[184]	new[184]	_	_
20-4	3791-3793	of	abstract[184]	new[184]	_	_
20-5	3794-3799	newly	abstract[184]|object[185]	new[184]|new[185]	_	_
20-6	3800-3809	published	abstract[184]|object[185]	new[184]|new[185]	_	_
20-7	3810-3816	papers	abstract[184]|object[185]	new[184]|new[185]	_	_
20-8	3817-3826	perfectly	_	_	_	_
20-9	3827-3833	depict	_	_	_	_
20-10	3834-3837	the	abstract[187]	giv[187]	_	_
20-11	3838-3848	scientific	organization[186]|abstract[187]	giv[186]|giv[187]	_	_
20-12	3849-3858	community	organization[186]|abstract[187]	giv[186]|giv[187]	_	_
20-13	3859-3861	’s	organization[186]|abstract[187]	giv[186]|giv[187]	_	_
20-14	3862-3871	authentic	abstract[187]	giv[187]	_	_
20-15	3872-3880	interest	abstract[187]	giv[187]	_	_
20-16	3881-3883	in	abstract[187]	giv[187]	_	_
20-17	3884-3888	this	abstract[187]|abstract[189]	giv[187]|giv[189]	_	_
20-18	3889-3900	flourishing	abstract[187]|abstract[189]	giv[187]|giv[189]	_	_
20-19	3901-3909	research	abstract[187]|abstract|abstract[189]	giv[187]|giv|giv[189]	_	_
20-20	3910-3915	field	abstract[187]|abstract[189]	giv[187]|giv[189]	_	_
20-21	3916-3917	.	_	_	_	_

#Text=Nevertheless , the first aim of this review is to disclose an overview of the latest applications of EVs as drug delivery vehicles , focusing on the sources employed , the molecules selected , and the final intended targets .
21-1	3918-3930	Nevertheless	_	_	_	_
21-2	3931-3932	,	_	_	_	_
21-3	3933-3936	the	abstract[190]	new[190]	_	_
21-4	3937-3942	first	abstract[190]	new[190]	_	_
21-5	3943-3946	aim	abstract[190]	new[190]	_	_
21-6	3947-3949	of	abstract[190]	new[190]	_	_
21-7	3950-3954	this	abstract[190]|abstract[191]	new[190]|giv[191]	coref	22-6[200_191]
21-8	3955-3961	review	abstract[190]|abstract[191]	new[190]|giv[191]	_	_
21-9	3962-3964	is	_	_	_	_
21-10	3965-3967	to	_	_	_	_
21-11	3968-3976	disclose	_	_	_	_
21-12	3977-3979	an	abstract[192]	new[192]	_	_
21-13	3980-3988	overview	abstract[192]	new[192]	_	_
21-14	3989-3991	of	abstract[192]	new[192]	_	_
21-15	3992-3995	the	abstract[192]|abstract[193]	new[192]|new[193]	_	_
21-16	3996-4002	latest	abstract[192]|abstract[193]	new[192]|new[193]	_	_
21-17	4003-4015	applications	abstract[192]|abstract[193]	new[192]|new[193]	_	_
21-18	4016-4018	of	abstract[192]|abstract[193]	new[192]|new[193]	_	_
21-19	4019-4022	EVs	abstract[192]|abstract[193]|abstract	new[192]|new[193]|giv	coref	22-28
21-20	4023-4025	as	abstract[192]|abstract[193]	new[192]|new[193]	_	_
21-21	4026-4030	drug	abstract[192]|abstract[193]|substance	new[192]|new[193]|giv	_	_
21-22	4031-4039	delivery	abstract[192]|abstract[193]|abstract	new[192]|new[193]|giv	_	_
21-23	4040-4048	vehicles	abstract[192]|abstract[193]	new[192]|new[193]	_	_
21-24	4049-4050	,	_	_	_	_
21-25	4051-4059	focusing	_	_	_	_
21-26	4060-4062	on	_	_	_	_
21-27	4063-4066	the	abstract[197]	new[197]	_	_
21-28	4067-4074	sources	abstract[197]	new[197]	_	_
21-29	4075-4083	employed	_	_	_	_
21-30	4084-4085	,	_	_	_	_
21-31	4086-4089	the	object[198]	giv[198]	_	_
21-32	4090-4099	molecules	object[198]	giv[198]	_	_
21-33	4100-4108	selected	_	_	_	_
21-34	4109-4110	,	_	_	_	_
21-35	4111-4114	and	_	_	_	_
21-36	4115-4118	the	abstract[199]	new[199]	_	_
21-37	4119-4124	final	abstract[199]	new[199]	_	_
21-38	4125-4133	intended	abstract[199]	new[199]	_	_
21-39	4134-4141	targets	abstract[199]	new[199]	_	_
21-40	4142-4143	.	_	_	_	_

#Text=In the second part of the review , we will take a step back and bring attention to the basics of one of the main pitfalls concerning EVs : the urgent need for highly pure vesicle preparation .
22-1	4144-4146	In	_	_	_	_
22-2	4147-4150	the	_	_	_	_
22-3	4151-4157	second	_	_	_	_
22-4	4158-4162	part	_	_	_	_
22-5	4163-4165	of	_	_	_	_
22-6	4166-4169	the	abstract[200]	giv[200]	_	_
22-7	4170-4176	review	abstract[200]	giv[200]	_	_
22-8	4177-4178	,	_	_	_	_
22-9	4179-4181	we	person	giv	_	_
22-10	4182-4186	will	_	_	_	_
22-11	4187-4191	take	_	_	_	_
22-12	4192-4193	a	abstract[202]	new[202]	_	_
22-13	4194-4198	step	abstract[202]	new[202]	_	_
22-14	4199-4203	back	_	_	_	_
22-15	4204-4207	and	_	_	_	_
22-16	4208-4213	bring	_	_	_	_
22-17	4214-4223	attention	abstract	new	_	_
22-18	4224-4226	to	_	_	_	_
22-19	4227-4230	the	abstract[204]	new[204]	_	_
22-20	4231-4237	basics	abstract[204]	new[204]	_	_
22-21	4238-4240	of	abstract[204]	new[204]	_	_
22-22	4241-4244	one	abstract[204]|abstract[205]	new[204]|new[205]	_	_
22-23	4245-4247	of	abstract[204]|abstract[205]	new[204]|new[205]	_	_
22-24	4248-4251	the	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-25	4252-4256	main	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-26	4257-4265	pitfalls	abstract[204]|abstract[205]|abstract[206]	new[204]|new[205]|new[206]	_	_
22-27	4266-4276	concerning	_	_	_	_
22-28	4277-4280	EVs	abstract	giv	appos	22-30[208_0]
22-29	4281-4282	:	_	_	_	_
22-30	4283-4286	the	abstract[208]	giv[208]	_	_
22-31	4287-4293	urgent	abstract[208]	giv[208]	_	_
22-32	4294-4298	need	abstract[208]	giv[208]	_	_
22-33	4299-4302	for	abstract[208]	giv[208]	_	_
22-34	4303-4309	highly	abstract[208]|abstract[210]	giv[208]|new[210]	_	_
22-35	4310-4314	pure	abstract[208]|abstract[210]	giv[208]|new[210]	_	_
22-36	4315-4322	vesicle	abstract[208]|object|abstract[210]	giv[208]|new|new[210]	_	_
22-37	4323-4334	preparation	abstract[208]|abstract[210]	giv[208]|new[210]	_	_
22-38	4335-4336	.	_	_	_	_
